Indo Borax appoints CEO after 64.26% Kronox buy

Deal completion triggers leadership change

Indo Borax & Chemicals said it has completed the acquisition of a 64.26% equity stake in Kronox Lab Sciences Limited and has appointed Suresh Kalra as Managing Director and Chief Executive Officer. The appointment was disclosed on October 1, 2026, after the acquisition closed. The company filed an intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing also referenced an earlier disclosure dated August 20, 2026, when the share purchase agreement (SPA) was executed. Indo Borax said there were no changes in the details required under Regulation 30 read with Schedule III compared with the original disclosure. The transaction marks a clear shift in control, with Indo Borax moving into a promoter role in Kronox.

What Indo Borax disclosed under SEBI Regulation 30

In its October 1 filing, Indo Borax confirmed two linked events: completion of the acquisition and the subsequent appointment of a new MD and CEO for Kronox Lab Sciences. The disclosure was positioned as a continuation of the earlier SPA announcement made on August 20, 2026. Indo Borax stated that no other details that are required to be disclosed under Regulation 30 and Schedule III had changed since the original intimation. This kind of clarification matters because it signals that key transaction terms and disclosure obligations remain consistent across the two filings. The company also reiterated its commitment to timely disclosure of material information under SEBI Regulation 30. The filing named Company Secretary Nikhil Goswami in the context of adherence to listing regulations and applicable laws.

Stake acquired, pricing, and the off-market mechanism

Separate takeover-related disclosures show Indo Borax & Chemicals and Zenrock Chemicals Private Ltd acquired a 64.26% stake in Kronox Lab Sciences, amounting to 2.38 crore shares, at Rs 103.22 per share. The transaction was executed through an off-market share purchase agreement. Indo Borax is identified as the acquirer alongside Zenrock as a person acting in concert (PAC) under takeover regulations. The acquisition consideration cited for the promoter stake transaction was ₹246 crore in Kronox’s regulatory filing referenced in the provided material. After the deal, Indo Borax becomes the new promoter of Kronox, while Zenrock is classified as a promoter-group entity.

Open offer and promoter reclassification details

The acquisition triggers a mandatory open offer for public shareholders under takeover regulations. Indo Borax, together with Zenrock as PAC, will make an offer to acquire up to 95.7 lakh shares, representing 25.79% of Kronox’s equity. The same set of filings also notes that the sellers (founding promoters) collectively held 74.21% before the transaction and will retain an aggregate 9.95% stake after completion. The sellers are expected to cease control and be reclassified as public shareholders upon completion, while Indo Borax becomes the promoter. This sequence is consistent with a change in management and control, which is also reflected in the MD and CEO appointment disclosed on October 1, 2026.

Kronox Lab Sciences: business, footprint, and product mix

Kronox Lab Sciences Limited was incorporated in 2008 and is headquartered in Vadodara, Gujarat. The company manufactures high-purity speciality fine chemicals, including excipients, reagents, buffers, and intermediates. Disclosures also describe the company’s presence in high purity fine and inorganic chemicals, including phosphates and metallic chemicals. Kronox’s portfolio is stated to include about 185 products, spanning excipients and ingredients, high purity reagents, and chemical products used across pharmaceuticals, nutraceuticals, and food applications. The company’s website and exchange identifiers are referenced in the provided material, including BSE: 544187 and NSE: KRONOX.

Financial snapshot: FY26 and recent quarterly numbers

Kronox reported revenue of approximately ₹101 crore and profit after tax of approximately ₹28 crore for FY26, as stated in the provided text. It also disclosed unaudited financial results for the quarter ended December 31, 2025 (Q3 FY26), showing revenue from operations of ₹25.27 crore and profit after tax of ₹6.59 crore. For the nine months ended December 31, 2025, the company reported revenue of ₹75.09 crore and profit after tax of ₹19.66 crore. These figures were presented as part of results approved by the Board on February 14, 2026, and published in newspapers on February 16, 2026 under SEBI requirements.

Key figures at a glance

Timeline of takeover disclosures and filings

The takeover process includes multiple dated disclosures, including a Public Announcement on August 20, 2026, a Detailed Public Statement on August 28, 2026, and a Draft Letter of Offer dated September 4, 2026. Indo Borax’s October 1, 2026 filing then confirmed completion of the acquisition and the management appointment. Separately, Kronox also filed a compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026. The certificate was issued by KFin Technologies Limited on April 1, 2026, and confirmed reporting of dematerialisation and rematerialisation details to stock exchanges.

Market context: listed in 2024, price reference and classification

The provided material describes Kronox as a Gujarat speciality chemicals company that listed on stock exchanges in 2024. It also categorises the stock on NSE as KRONOX in the Chemicals sector and Small Cap segment. A price reference in the supplied text indicates Kronox Lab Sciences’ share price was ₹172.55 on NSE and ₹172.8 on BSE as on September 9, 2026. These prices are presented as contextual market reference points alongside the acquisition pricing disclosed in takeover filings.

Why the leadership appointment matters for investors

The appointment of a new Managing Director and CEO immediately after completion of a controlling stake acquisition is a formal signal that operational oversight is shifting to the new promoter group. In this case, the appointment follows the confirmation that Indo Borax has completed the 64.26% acquisition, which aligns with the stated change in management and control. For public shareholders, the open offer process and the reclassification of earlier promoters to public shareholders are the key regulatory steps that frame near-term governance changes. The disclosures also emphasise compliance language, including confirmation that Regulation 30 and Schedule III disclosure requirements remain unchanged since the original SPA intimation.

Conclusion

Indo Borax & Chemicals has confirmed it now holds a controlling 64.26% stake in Kronox Lab Sciences and has appointed Suresh Kalra as MD and CEO effective October 1, 2026. The transaction, executed off-market at Rs 103.22 per share for 2.38 crore shares, also triggers an open offer for up to 25.79% of equity. Kronox continues to report its operational and financial updates through standard SEBI channels, including results publications and depository compliance certifications. The next milestones in the takeover process remain linked to the open offer documentation already reflected in the public announcement, detailed public statement, and draft letter of offer timeline.